Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Theravance Biopharma is a late-stage biopharmaceutical company focused on organ-selective medicines for respiratory and gastrointestinal diseases. The company's lead asset is ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH), with additional programs in acute bacterial skin infections and lung infections. With minimal current revenue (~$100M TTM from royalties/milestones), TBPH operates as a clinical-stage biotech dependent on successful drug approvals and commercialization partnerships.
TBPH currently generates limited revenue primarily through royalty streams from previously divested or partnered respiratory assets. The company's value proposition centers on advancing ampreloxetine through FDA approval for nOH (a rare disease affecting ~500,000 US patients), where it could command premium pricing given limited treatment options. The business model relies on either direct commercialization with specialty sales force or strategic partnerships to monetize approved therapies. With 100% gross margins on royalty income but -73% operating margins, the company burns cash funding clinical trials and regulatory submissions while awaiting approval catalysts.
FDA regulatory decisions on ampreloxetine NDA for neurogenic orthostatic hypotension
Clinical trial data readouts for pipeline programs (Phase 2/3 results, safety signals)
Partnership announcements or licensing deals that provide non-dilutive funding
Cash runway updates and equity financing events (dilution risk drives volatility)
Competitive developments in nOH treatment landscape or biosimilar threats to royalty streams
Binary FDA approval risk for ampreloxetine - rejection would eliminate primary value driver and potentially require strategic alternatives
Pricing pressure from Medicare drug negotiation policies (IRA) could limit commercial upside for approved rare disease therapies
Patent cliff risk on legacy royalty-generating assets as exclusivity periods expire, eliminating current revenue base
Competitive nOH treatments from Lundbeck (droxidopa/Northera) and potential new entrants could limit market share and pricing power
Larger pharma companies with superior commercial infrastructure may out-execute on specialty drug launches if TBPH pursues independent commercialization
Cash burn of ~$70-80M annually creates ongoing dilution risk if capital markets become unfavorable before achieving profitability
Concentration risk in royalty revenue streams - loss of key legacy partnerships would eliminate near-term cash generation
low - Biopharmaceutical development timelines and FDA approval processes are largely insulated from GDP fluctuations. Rare disease treatments like nOH therapies maintain demand regardless of economic conditions. However, severe recessions could impact partnership valuations and access to capital markets for financing.
Rising interest rates negatively impact TBPH through two channels: (1) higher discount rates compress NPV of future drug cash flows, disproportionately affecting pre-revenue biotechs with distant payoffs, and (2) increased competition from risk-free yields makes speculative biotech investments less attractive, reducing valuation multiples. The company's $950M cash position benefits from higher yields on marketable securities, partially offsetting valuation pressure.
Moderate - While TBPH has minimal debt (0.19 D/E ratio), access to capital markets is critical for funding operations until profitability. Credit market dislocations or risk-off sentiment can shut down biotech financing windows, forcing dilutive equity raises or asset sales. The company's 9.48x current ratio provides substantial liquidity buffer, reducing near-term refinancing risk.
growth - TBPH attracts speculative biotech investors focused on binary FDA approval catalysts and M&A potential. The 101% one-year return reflects momentum following positive clinical/regulatory developments. With negative cash flow and no dividends, the stock appeals to risk-tolerant growth investors willing to underwrite multi-year drug development timelines for asymmetric upside.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial readouts, FDA decisions). The 40% six-month return demonstrates event-driven price action. Small market cap ($1B) and limited float amplify volatility, with typical beta >1.5 versus broader market.
